



ASX/MEDIA RELEASE

ASX: MLA 13 November 2015

MEDIVET BIOLOGICS US ANIMAL HEALTH BUSINESS


The Company reports that the process commenced in June 2015 for the divestment/dilution of the US Medivet Biologics business has not to date produced any viable options.

A sale agreement had recently reached an advance stage of negotiation with an industry party after due diligence but has not proceeded. The Directors are continuing to explore all options for disposal/divestment of the US business including any necessary provisioning for its interest therein in the half-year accounts.

The Company's human health business continues to perform to plan.

By Order of the Board

Ian Mitchell
Company Secretary/Director



abn 30 096 048 912
Unit 4B, 128-130 Frances Street, Lidcombe NSW 2141 Australia
PO Box 445, Lidcombe NSW 2141
T +612 9466 5300 F +612 9922 7165
www.medaust.com